- Home
- SNDL vs RIGL Comparison
SNDL vs RIGL Comparison
Compare SNDL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDL
- RIGL
- Stock Information
- Founded
- SNDL 2006
- RIGL 1996
- Country
- SNDL Canada
- RIGL United States
- Employees
- SNDL N/A
- RIGL N/A
- Industry
- SNDL Pharmaceuticals and Biotechnology
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SNDL Health Care
- RIGL Health Care
- Exchange
- SNDL Nasdaq
- RIGL Nasdaq
- Market Cap
- SNDL 651.1M
- RIGL 335.5M
- IPO Year
- SNDL 2019
- RIGL 2000
- Fundamental
- Price
- SNDL $2.68
- RIGL $38.85
- Analyst Decision
- SNDL
- RIGL Buy
- Analyst Count
- SNDL 0
- RIGL 5
- Target Price
- SNDL N/A
- RIGL $38.20
- AVG Volume (30 Days)
- SNDL 4.9M
- RIGL 995.6K
- Earning Date
- SNDL 07-31-2025
- RIGL 08-05-2025
- Dividend Yield
- SNDL N/A
- RIGL N/A
- EPS Growth
- SNDL N/A
- RIGL N/A
- EPS
- SNDL N/A
- RIGL 5.43
- Revenue
- SNDL $692,339,389.00
- RIGL $267,921,000.00
- Revenue This Year
- SNDL $5.52
- RIGL $59.93
- Revenue Next Year
- SNDL $4.09
- RIGL N/A
- P/E Ratio
- SNDL N/A
- RIGL $7.15
- Revenue Growth
- SNDL 3.54
- RIGL 105.62
- 52 Week Low
- SNDL $1.15
- RIGL $12.66
- 52 Week High
- SNDL $2.74
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- SNDL 82.41
- RIGL 68.57
- Support Level
- SNDL $2.07
- RIGL $39.00
- Resistance Level
- SNDL $2.74
- RIGL $42.08
- Average True Range (ATR)
- SNDL 0.14
- RIGL 2.32
- MACD
- SNDL 0.05
- RIGL -0.37
- Stochastic Oscillator
- SNDL 92.50
- RIGL 53.26
About SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.